Final Program [International Conference on AIDS (14th: 2002: Barcelona, Spain)]

Poster Exhibitions

Wednesday July 1o

WePeB5843 The impact of depression and substance abuse
on antiretroviral treatment adherence in newlytreated individuals with HIV infection
CM Dezii, S Grandy, B Burtcel, S Hodder,
H Kawabata (United States)
WePeB5844 A single, untimed determination of drug levels
after starting therapy is a significant predictor of
mortality after starting antiretroviral therapy
CS A Alexander, J Asselin, R S Hogg,
JS G Montaner, M V 0 O'Shaughnessy, L Ting,
P R Harrigan (Venezuela)
WePeB5845 Differences between provider-estimated and selfreported adherence to antiretroviral therapy
S Mannheimer, M Perkins, J Ford, B Diamond,
L Farrell, S Findley, A Hofmann, W EI-Sadr
(United States)
WePeB5846 Self-efficacy expectation and adherence to
antiretroviral therapy in H IV infected patients: a
cross-sectional study in Southern Brazil
CA T Pinheiro, J CC Leite, M L Drachler,
V L Silveira, M 0 Centeno (Brazil)
WePeB5847 HIV medication adherence assessment: a novel
low literacy self-report tool compared to
electronic Medication Event Monitoring System
(MEMS) data
L M Kunches, E Coakley, K Neill, D Marquis,
D Dean, J DeCristofaro, L Ruhlmann, J Musolino
(United States)
WePeB5848 Adherence to antiretroviral therapy in Kampala,
Uganda
C Kityo', M Rabkin2, D Atwine', G Mulindwa',
A Kebba', G Kabuye', P Mugyenyi'
(Uganda; 2United States)
WePeB5849 Social support and social networks: the
challenge for adherence to HIV/AIDS antiviral
treatment in a sample of patients in Puerto Rico
I Anduar-Bello', J Toro-Alfonso', R Amico2,
SD Fisher ('Puerto Rico; 2 United States)
WePeB585o Adherence to HAART, HIV-1 RNA level, and
genotypic resistance among injection drug users
in Baltimore, Maryland, USA
M KLin, A Sethi, A W Wu, SA Strathdee,
D D Celentano, D Vlahov (United States)
WePeB5851 Determinants of antiretroviral treatment
adherence among patients with HIV and AIDS in
Botswana
S D Weiser', W R Wolfe', P Kebaabetswe2,
J Makhema2, D Dickenson2, K F Mompati2,
M K Sherif, S Tlou2, H Moffat2, C Onen2,
K Hensle', I Thior2, R G Marlink'
('United States; 2Botswana)
WePeB5852 Adherence to antiretroviral therapy: comparative
analysis of protease inhibitors-based and nonnucleoside reverse transcriptase inhibitors-based
regimens
A Antinori', M P Trotta', A Cozzi Lepri2,
M Zaccarelli', L Minardi', P Narciso', L Ravasio',
R Murri', F Baldelli', P Piano', S Lo Caputo',
P De Longis', P Noto', S Nappa', M Dalessandro',
A W Wu3, M Moroni', G Ippolito', A d'Arminio
Monforte', A Ammassari'
('Italy; 2United Kingdom; 3United States)
WePeB5853 A novel method for visualising individual
electronic monitoring adherence data
K Fennie, G Knafl, C Bova, K Dieckhaus,
A Williams (United States)

WePeB5854 Adherence as a gender issue: psychosocial
factors influencing antiretroviral adherence in
HIV-seropositive women
F Starace', N Abrescial, G Angarano', L Cafaro',
G Guaraldi', S Lo Caputo', R Maserati', A Massa',
A Tramarin', A Chirianni', L Sherr2
('Iltaly; 'United Kingdom)
WePeB5855 Improved tolerability and adherence with enteric
coated didanosine capsules (VidexEC~) versus
buffered tablets (Videx@)
S K Chuck D Areff (United States)
WePeB5856 Gender-related factors influencing medication
and clinic visit adherence in HIV/AIDS patients
S J Sorensen, H A Klinge, V L Mravca-Wilkey,
I Elzey, K H Fife (United States)
WePeB5857 Closely supervised intervention pilot program to
improve adherence among urban indigent women
M Caprio, E Homer, L E Laufman, T Banks, T Zerai,
S Nettles, P Byrd, J K Levy, F Visnegarwala
(United States)
WePeB5858 Adherence to maternal and infant zidovudine in a
pilot study to prevent mother to child HIV
transmission associated with breastfeeding,
Botswana
S Lockman', R L Shapiro', I Thior2, L Stocking2,
C Wester2, T Peter2, P Kebaabetswe2, R Marlink', M
Essex', S J Heymann' ('United States; 2Botswana)
WePeB5859 Cultural dimensions that impact adherence to
treatment of Puerto Ricans with the HIV: developing
a model for culturally competent health care
A R Braia L Eldred, J R Morales, M Lago
(United States)
WePeB586o Causes of ARV Failure In India
D G Saple, S B Vaidya, R D Kharkar, VP Pandey,
R Vedrevu, J P Ramnanai, S Arsad (India)
WePeB5861 Application of a multidisplicinary programme of
adherence to antiretroviral treatment. Preliminary
results
M Bernaus, L Fernandez, G Navarro, A Torres,
P Bescos, M Perez, M Sala, M Cervantes, F Segura
(Spain)
WePeB5862 Predicting acceptance of highly active
antiretroviral treatment (HAART): the role of
patients' perceptions of illness and treatment
R Horne, V Cooper, G Gellaitry, N Lambert,
M Fisher (United Kingdom)
WePeB5863 Predicting non-adherence to HAART: the role of
patients' doubts about personal need and
concerns about potential adverse effects
R Homrne, V Cooper, M Fisher (United Kingdom)
WePeB5864 Twelve-week outcome of a cue-controlled paging
system to increase ART adherence
S A Safren ES Hendriksen, S Boswell,
N DeSousa, K H Mayer (United States)
WePeB5865 A comparison of resistance propensity between
NNRTIs and PIs (protease inhibitors) in VA New
Jersey Health Care System
R H K Eng, L L Dever, M Sasanpour, I Meltzer
(United States)
WePeB5866 Determinants of adherence to antiretroviral
therapy in a developing country
SB May G Cardoso, P F Barroso (Brazil)
WePeB5867 Efficacy of a counseling intervention on
adherence to HAART: results of a French
prospective controlled study
L Bentz, C Pradier, M Morin, B Spire, M Rebillon,
M Souville, I G Fuzibet, A Pesce, P Dellamonica,

C Tourette-Turgis, I P Moatti (France)

Wednesday

XIV International AIDS Conference BARCELONA - JULY 7-12

159